$VIRI News
Last published 2y ago
- 2y agoVIRIDWTXVirios Therapeutics, Inc. and Wex Pharmaceuticals, Inc. Announce Business Combination to Form Dogwood Therapeutics, Inc. (Nasdaq: "DWTX")GlobeNewswireStrategic financing by an affiliate of CK Life Sciences Int'l., (Holdings) Inc., results in working capital of approximately $23 million to fund operations and advance Phase 2b Halneuron® development into 4Q25
- 2y agoVIRIVirios Therapeutics Announces Second Quarter 2024 Financial ResultsGlobeNewswire- Bateman Horne Center completed enrollment in its groundbreaking investigator-initiated Long-COVID phase 2a study featuring valacyclovir and celecoxib (IMC-2) - - Top-line results from the Bateman Horne Center's
- 2y agoVIRIVirios Therapeutics to Report Second Quarter 2024 Financial Results on Thursday, August 8, 2024GlobeNewswireATLANTA, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating
- 2y agoVIRIVirios Therapeutics Announces Completion of Enrollment in IMC-2 Phase 2 Long-COVID Study Being Conducted by Bateman Horne CenterGlobeNewswire- Virios projects releasing top line results from this groundbreaking Proof of Concept study in October 2024 - - Published data indicates increased Epstein-Barr herpes virus in Long-COVID patients, highlighting
- 2y agoVIRIVirios Therapeutics Announces Closing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyGlobeNewswireATLANTA, May 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechnology company focused on advancing novel antiviral therapies to
- 2y agoVIRIVirios Therapeutics Announces Pricing of $1.7 Million Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyGlobeNewswireATLANTA, May 19, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechnology company focused on advancing novel antiviral therapies to
- 2y agoVIRIVirios Therapeutics Announces Proposed Public Offering of Common Stock to Commence Preparations for Planned IMC-2 Long-COVID Phase 2b StudyGlobeNewswireATLANTA, May 17, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company" or "Virios Therapeutics"), a development-stage biotechnology company focused on advancing novel antiviral therapies to
- 2y agoVIRIVirios Therapeutics, Inc. (VIRI) Q1 2024 Earnings Call TranscriptEarnings Call Transcripts
- 2y agoVIRIVirios Therapeutics Announces First Quarter 2024 Financial Results and Provides Corporate UpdateGlobeNewswire- Top-line results from the ongoing investigator-initiated Bateman Horne Center Long-COVID phase 2 featuring valacyclovir and celecoxib (IMC-2) expected in the second-half of 2024 - - Conference Call Today at 8:30 a.m.
- 2y agoVIRIVirios Therapeutics to Report First Quarter 2024 Financial Results on Thursday, May 9, 2024GlobeNewswireATLANTA, May 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic
- 2y agoVIRIVirios Therapeutics Announces Publication of International Patent for IMC-2 Covering Antiviral Treatment of Long-COVIDGlobeNewswire- New patent would extend coverage and expand potential value of Virios' antiviral pipeline globally – - Active Long-COVID characterized by immune dysfunction leading to recurrent herpesviruses reactivation - -
- 2y agoVIRIVirios Therapeutics Announces Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswireATLANTA, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic
- 2y agoVIRIVirios Therapeutics Issues Shareholder Letter Highlighting Corporate Progress and Key Upcoming MilestonesGlobeNewswireATLANTA, Ga., Feb. 28, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating
- 2y agoVIRIVirios Therapeutics Announces Plans to Advance Development of IMC-2 as Treatment for Symptoms Associated with Long-COVIDGlobeNewswire- Placebo-Controlled Clinical Proof of Concept Data Expected in Mid-2024 -- Targeting Initiation of IMC-2 Phase 2 program in 2H 2024 - ATLANTA, Jan. 22, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI)
- 2y agoVIRIVirios Therapeutics, Inc. Reaches Alignment with FDA on Requirements for Advancing Development Candidate IMC-2 as Treatment for Long-COVIDGlobeNewswireATLANTA, Jan. 02, 2024 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on developing novel antiviral therapies to treat debilitating
- 3y agoVIRIVirios Therapeutics, Inc. (VIRI) Q3 2023 Earnings Call TranscriptEarnings Call Transcripts
- 3y agoVIRIVirios Therapeutics Announces Third Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswire- Conference Call Today at 8:30 a.m. ET - ATLANTA, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel
- 3y agoVIRIVirios Therapeutics to Report Third Quarter 2023 Financial Results on Monday, November 13, 2023GlobeNewswireATLANTA, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat
- 3y agoVIRIVirios Therapeutics to Present at the ThinkEquity Conference on Thursday, October 19, 2023GlobeNewswireATLANTA, Oct. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating
- 3y agoVIRIVirios Therapeutics Announces Termination of At-The-Market Sales AgreementGlobeNewswireATLANTA, Sept. 18, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating
- 3y agoVIRIVirios Therapeutics CEO Greg Duncan to Present at the SHARE™️ Series Investor Event on Monday, September 18, 2023GlobeNewswireATLANTA, Sept. 12, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating
- 3y agoVIRIVirios Therapeutics Announces Halt to At-The-Market Offering SalesGlobeNewswireATLANTA, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic
- 3y agoVIRIVirios Therapeutics Announces Second Quarter 2023 Financial Results and Provides Corporate UpdateGlobeNewswire- Continued Progress in Expanding and Advancing Clinical Pipeline -- Conference Call Today at 8:30 a.m. ET - ATLANTA, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a
- 3y agoVIRIVirios Therapeutics Announces Plans to Advance Lead Candidate IMC-1 to Phase 3 Development as a New Treatment Option for FibromyalgiaGlobeNewswireATLANTA, Aug. 09, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic
- 3y agoVIRIVirios Therapeutics Announces Positive Data Demonstrating Improvement in Multiple Long-COVID Symptoms Following Treatment with a Combination of Valacyclovir and Celecoxib in an Exploratory, Open-Label, Proof of Concept StudyGlobeNewswireATLANTA, July 17, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic
- 3y agoVIRIVirios Therapeutics Regains Compliance with Nasdaq Minimum Bid Price RequirementGlobeNewswireATLANTA, May 25, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a clinical‐stage biopharmaceutical company, today announced that it has regained compliance with the minimum bid price
- 3y agoVIRIVirios Therapeutics Announces Submission of Final Toxicology Results to Support Proposed Phase 3 Program for Novel Therapy to Treat FibromyalgiaGlobeNewswireATLANTA, May 15, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic
- 3y agoVIRIVirios Therapeutics Announces First Quarter 2023 Financial ResultsGlobeNewswireATLANTA, May 11, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic
- 3y agoVIRIVirios Therapeutics to Report First Quarter 2023 Financial Results on Thursday, May 11, 2023GlobeNewswireATLANTA, Ga., May 04, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat
- 3y agoVIRIVirios Therapeutics Announces Initial FDA Feedback on Proposed IMC-1 Phase 3 Program for Treatment of FibromyalgiaGlobeNewswire-Virios' IMC-1 Phase 3 Proposed Program is Considered Acceptable based on Initial FDA Feedback Pending Review of the Final Chronic Toxicology Program Results- -Final Toxicology Results to be Submitted to FDA in May
- 3y agoVIRIVirios Therapeutics Announces Fourth Quarter and Full Year 2022 Financial ResultsGlobeNewswireATLANTA, March 14, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (NASDAQ:VIRI) (the "Company"), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating
- 3y agoVIRIVirios Therapeutics to Report Fourth Quarter and Full Year 2022 Financial Results on Tuesday, March 14, 2023GlobeNewswireATLANTA, March 07, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel antiviral therapies to treat debilitating chronic diseases,
- 3y agoVIRIVirios Therapeutics Announces Exploratory Long-COVID Trial Top-Line Data, Featuring Combination of Valacyclovir and Celecoxib, Projected in June 2023GlobeNewswireATLANTA, Feb. 13, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic
- 3y agoVIRIVirios Therapeutics Announces Scheduling of FDA Meeting in March 2023 to Discuss IMC-1 Fibromyalgia Phase 3 ProgramGlobeNewswireATLANTA, Jan. 05, 2023 (GLOBE NEWSWIRE) -- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic
- 3y agoVIRIVirios Therapeutics, Inc. to Present at the Virtual Planet MicroCap ShowcaseBusiness WireVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today
- 3y agoVIRIVirios Therapeutics Announces Third Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire- FORTRESS Study Analysis Reveals Fibromyalgia Patients New to Research Demonstrate Significant IMC-1 Pain Reduction Treatment Benefits - - Company Believes FORTRESS Safety Data Supports Phase 3 Development, Requesting
- 4y agoVIRIVirios Therapeutics to Report Third Quarter 2022 Financial Results and Provide Corporate Update on Monday, November 14, 2022Business WireVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced
- 4y agoVIRIVirios Therapeutics, Inc. Announces Closing of Public OfferingBusiness WireVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the closing of its previously
- 4y agoVIRIVirios Therapeutics, Inc. Announces Pricing of Public OfferingBusiness WireVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today the pricing of its underwritt
- 4y agoVIRIVirios Therapeutics, Inc. Announces Proposed Public OfferingBusiness WireVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that it intends to offer to s
- 4y agoVIRIVirios Therapeutics Announces Top-Line Results from Phase 2b Study of IMC-1 in FibromyalgiaBusiness WireVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia ("FM"), today announced topline results from i
- 4y agoSWISFVIRINew to The Street TV Announces Four Corporate Interviews on its 384th TV Show, Airing on the Fox Business Network, Tonight, Monday, September 12, 2022, at 10:30 PM PTGlobeNewswireNEW YORK, Sept. 12, 2022 (GLOBE NEWSWIRE) -- FMW Media's New to The Street TV, a nationally syndicated TV show, announces episode #384, airing on Fox Business Network tonight, Monday, September 12, 2022, at 10:30 PM PT. The New to The Street show
- 4y agoVIRIVirios Therapeutics' Announces Dosing of First Patient in IMC-2 Long-COVID Treatment TrialBusiness Wire-New Long-COVID Research Program Complements Fibromyalgia Phase 2b Clinical Research Program- Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat deb
- 4y agoVIRIVirios Therapeutics Announces Second Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire- Top Line FORTRESS Study Data Expected in September 2022 - - Conference Call Today at 8:30 a.m. ET - Virios Therapeutics, Inc. (NASDAQ:VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to
- 4y agoVIRIVirios Therapeutics, Inc. to Present at Investor Summit Group's Q3 Virtual ConferenceBusiness WireVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, today announced that Greg Duncan, Chairman an
- 4y agoVIRIVirios Therapeutics to Report Second Quarter 2022 Financial Results and Provide Corporate Update on Thursday, August 11, 2022Business WireVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its second quarter 2022
- 4y agoVIRIVirios Therapeutics' Study Featured in Peer-Reviewed Journal Publication Highlighting Association of Herpes Simplex Type 1 Viral Infection with Common Gastrointestinal Disorders, Including in Patients with Comorbid FibromyalgiaBusiness WireStudy Demonstrates Potential Utility of Combination Antiviral Drug Therapies, to Treat Patients with Chronic Illnesses such as Fibromyalgia and Irritable Bowel Syndrome Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology compa
- 4y agoVIRIVirios Therapeutics Announces First Quarter 2022 Financial Results and Provides Corporate UpdateBusiness Wire- Enrollment Completed in FORTRESS Study with Top Line Data Expected in September 2022 - - Conference Call Today at 8:30 a.m. ET - Virios Therapeutics, Inc. (NASDAQ:VIRI), a development-stage biotechnology company focused on advancing novel, combi
- 4y agoVIRIVirios Therapeutics to Report First Quarter 2022 Financial Results and Provide Corporate Update on Thursday, May 12, 2022Business WireVirios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic diseases, including fibromyalgia, announced today that its first quarter 2022 f
- 4y agoVIRIVirios Therapeutics Completes Enrollment of 425 Patients in Phase 2b "FORTRESS" Clinical Trial for FibromyalgiaBusiness Wire- Top line Data from the FORTRESS Study Expected in September 2022 - Virios Therapeutics, Inc. (Nasdaq: VIRI), a development-stage biotechnology company focused on advancing novel, combination antiviral therapies to treat debilitating chronic disease